ClinicalTrials.gg
CompletedNCT01491035Updated Mar 16, 2017Results posted

Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

A Phase 2 interventional study of Vortioxetine and Vortioxetine in Depressive Disorder and Anxiety Disorder, sponsored by H. Lundbeck A/S. Completed at 7 sites in 2 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2017-03-16.

Sponsored by H. Lundbeck A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
7 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing vortioxetine in Depressive Disorder — 1 open to participants now, 1 under way, none of them phase 3. Vortioxetine · Depressive Disorder.

Enrollment
9th of 10
48 · median 511
Started
2012
the only one that year
Phase 2
Only one
of the 10
Registered
8th of 10
by date
Lead sponsor
2 of 10
H. Lundbeck A/S

Among the 10 studies testing vortioxetine in Depressive Disorder, this one is the 9th largest by enrollment, is the only one that started in 2012, is the only one in phase 2, and was the 8th registered.

Depressive Disorder

855 studies on the registry are indexed under Depressive Disorder; 159 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

1 of the 10 studies testing vortioxetine in Depressive Disorder is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 7 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing vortioxetine in Depressive Disorder, or all of them as a file.
02

Study summary

The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder

Read the detailed description

The study will be conducted in the US and in Europe and will include paediatric patients diagnosed with depressive or anxiety disorders of two age populations; children aged 7-11 years and adolescents of the age 12-17 years. It is an open study to allow pharmacokinetic (PK) sampling of all patients and four dose levels will be tested. Following lower initial doses for 2 to 6 days, the patients will be treated once daily at the assigned dose levels for 14 days, and it is expected that patients may benefit from treatment during this period. As the treatment duration is not sufficient according to treatment guidelines, if judged or indicated by the investigator, the patients are offered to continue in an extension treatment of up to six months to allow possibility for therapeutic satisfaction.

Preferably, the cohorts will be dosed in the following order: AC1, AC2, CC1, AC3, CC2, AC4, CC3, and CC4. An external data safety monitoring board (DSMB) will be established to evaluate safety, tolerability and preliminary PK data from the dosed cohort(s) prior to any dosing of subsequent cohort (s). The dose regimen may be adjusted based on the recommendation of the DSMB. Adolescents will be exposed to a certain dose of vortioxetine before children receive the same dose.

03

Conditions studied

  • Depressive Disorder
  • Anxiety Disorder

Keywords

  • Children
  • Adolescents
  • Pharmacokinetic
  • Pharmacodynamic
04

Who can participate

Ages eligible
7 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of Depressive or Anxiety Disorder.
  • The patient and parent(s)/legal representative(s) are able to comprehend and satisfactorily comply with the protocol requirements.
  • Treatment with antidepressant therapy is warranted, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • The patient is pregnant or breast-feeding.
  • The patient presents or has a history of an Axis I () diagnosis of Bipolar Disorder, Post Traumatic Stress Disorder (PTSD), Autism, Pervasive Developmental Disorder (PDD), Obsessive Compulsive Disorder (OCD) or Schizophrenia or Schizoaffective Disorder.
  • The patient has not maintained a stable dose of a methylphenidate or amphetamine for their treatment of attention-deficit/hyperactivity disorder (ADHD) for a minimum of 4 weeks prior to the study treatment.
  • The patient has a known mental retardation, or clinical evidence or known social or school history indicative of mental retardation.
  • The patient is at significant risk of committing suicide based on history (for example previous suicide attempt) or according to the investigator's experience, or based on active suicidal ideation, intent or plan, item 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS).
  • The subject has any concurrent illness that may affect the particular target or absorption, distribution, and elimination of the medicinal product (IMP).
  • The patient meets DSM-IV-TR criteria for any psychoactive substance or alcohol use disorder.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort CC1, 6 children

    Drug: Vortioxetine

  • Experimental
    Cohort CC2, 6 children

    Drug: Vortioxetine

  • Experimental
    Cohort CC3, 6 children

    Drug: Vortioxetine

  • Experimental
    Cohort CC4, 6 children

    Drug: Vortioxetine

  • Experimental
    Cohort AC1, 6 adolescents

    Drug: Vortioxetine

  • Experimental
    Cohort AC2, 6 adolescents

    Drug: Vortioxetine

  • Experimental
    Cohort AC3, 6 adolescents

    Drug: Vortioxetine

  • Experimental
    Cohort AC4, 6 adolescents

    Drug: Vortioxetine

Interventions

  • 5 mg tablets for 14 days; orally; once daily

    Also known as: Brintellix

  • 10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily

    Also known as: Brintellix

  • 15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily

    Also known as: Brintellix

  • 20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily

    Also known as: Brintellix

06

What researchers measure

Primary outcomes

  1. Cmax of Vortioxetine

    Maximum plasma concentration of vortioxetine

    Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18, or 20, depending on assigned dose level

  2. AUC(0-24h) of Vortioxetine

    Area under the vortioxetine plasma concentration-time curve from 0 to 24 hours

    Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level

  3. t½ of Vortioxetine

    Half-life of vortioxetine in plasma

    Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level

  4. Cmax of Lu AA34443

    Maximum plasma concentration of the major, inactive metabolite Lu AA34443

    Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18, or 20, depending on assigned dose level

  5. AUC(0-24h) of Lu AA34443

    Area under the plasma concentration-time curve from 0 to 24 hours for the major, inactive metabolite Lu AA34443

    Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level

  6. t½ of Lu AA34443

    Half-life of the major, inactive metabolite Lu AA34443 in plasma

    Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level

  7. Oral Clearance (CL/F) of Vortioxetine

    Oral clearance expressed as a function of bioavailability

    Time frame: Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level

07

Results

Posted Jan 15, 2016

Participant flow

Participant flow — Overall Study
MilestoneAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
Started66666666
Completed66665666
Not completed00001000
Withdrew: Lost to follow-up00001000

Outcome measures

PrimaryCmax of Vortioxetine

Maximum plasma concentration of vortioxetine

Time frame:
Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18, or 20, depending on assigned dose level
Reported as:
Median · ng/mL
Cmax of Vortioxetine
ng/mLAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
Cmax of Vortioxetine4.3 ± 3.77.8 ± 2.815 ± 6.216 ± 8.15.0 ± 3.314 ± 8.226 ± 2131 ± 20
PrimaryAUC(0-24h) of Vortioxetine

Area under the vortioxetine plasma concentration-time curve from 0 to 24 hours

Time frame:
Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
Reported as:
Median · ng*h/mL
AUC(0-24h) of Vortioxetine
ng*h/mLAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
AUC(0-24h) of Vortioxetine82 ± 71144 ± 60283 ± 115304 ± 14389 ± 66261 ± 137492 ± 373562 ± 374
Primaryt½ of Vortioxetine

Half-life of vortioxetine in plasma

Time frame:
Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
Reported as:
Median · h
t½ of Vortioxetine
hAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
t½ of Vortioxetine46 ± 3356 ± 1950 ± 1640 ± 1045 ± 2752 ± 1871 ± 5262 ± 23
PrimaryCmax of Lu AA34443

Maximum plasma concentration of the major, inactive metabolite Lu AA34443

Time frame:
Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18, or 20, depending on assigned dose level
Reported as:
Median · ng/mL
Cmax of Lu AA34443
ng/mLAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
Cmax of Lu AA344433.5 ± 2.214 ± 7.116 ± 5.338 ± 127.8 ± 3.415 ± 5.420 ± 1347 ± 17
PrimaryAUC(0-24h) of Lu AA34443

Area under the plasma concentration-time curve from 0 to 24 hours for the major, inactive metabolite Lu AA34443

Time frame:
Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
Reported as:
Median · ng*h/mL
AUC(0-24h) of Lu AA34443
ng*h/mLAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
AUC(0-24h) of Lu AA3444356 ± 29223 ± 98266 ± 100544 ± 192115 ± 47241 ± 93429 ± 232646 ± 251
Primaryt½ of Lu AA34443

Half-life of the major, inactive metabolite Lu AA34443 in plasma

Time frame:
Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
Reported as:
Median · h
t½ of Lu AA34443
hAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
t½ of Lu AA3444326 ± 9.333 ± 1324 ± 1124 ± 5.120 ± 2419 ± 9.629 ± 6.127 ± 8.8
PrimaryOral Clearance (CL/F) of Vortioxetine

Oral clearance expressed as a function of bioavailability

Time frame:
Pre-dose and 1, 3, 5, 8, 12 and 24 hours post-dose on Day 14, 16, 18 or 20, depending on assigned dose level
Reported as:
Median · L/h
Oral Clearance (CL/F) of Vortioxetine
L/hAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
Oral Clearance (CL/F) of Vortioxetine60 ± 5550 ± 1650 ± 2361 ± 2050 ± 1642 ± 2529 ± 3334 ± 17

Adverse events

Collected over 4 to 5 weeks, depending on the assigned dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adolescents, 5 mg—0/6 (0%)4/6 (66.7%)
Adolescents, 10 mg—0/6 (0%)4/6 (66.7%)
Adolescents, 15 mg—0/6 (0%)5/6 (83.3%)
Adolescents, 20 mg—0/6 (0%)5/6 (83.3%)
Children, 5 mg—0/6 (0%)5/6 (83.3%)
Children, 10 mg—0/6 (0%)5/6 (83.3%)
Children, 15 mg—0/6 (0%)5/6 (83.3%)
Children, 20 mg—0/6 (0%)4/6 (66.7%)
Most frequent other events
Showing 10 of 41
Most frequent other events
EventAdolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mg
Abdominal pain upperGastrointestinal disorders0/60/61/60/63/61/63/60/6
NauseaGastrointestinal disorders2/61/63/62/62/60/61/60/6
VomitingGastrointestinal disorders0/61/61/60/61/60/63/60/6
HeadacheNervous system disorders3/61/62/61/62/60/62/61/6
SedationNervous system disorders1/61/63/62/63/60/61/60/6
Abdominal painGastrointestinal disorders0/60/60/60/62/60/60/60/6
FatigueGeneral disorders2/62/60/61/60/60/61/60/6
IrritabilityGeneral disorders2/60/60/60/60/60/60/61/6
Decreased appetiteMetabolism and nutrition disorders0/62/60/60/60/60/60/61/6
AkathisiaNervous system disorders0/62/60/60/60/60/60/60/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)Adolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mgTotal
Mean15.7 ± 1.915.3 ± 1.915.2 ± 1.214.8 ± 1.910.3 ± 1.29.7 ± 1.210.5 ± 0.89.8 ± 1.812.7 ± 3.0
Sex: Female, Male
Sex: Female, Male(Participants)Adolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mgTotal
Female3354332225
Male3312334423
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Adolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mgTotal
American Indian or Alaska Native000000000
Asian000000000
Native Hawaiian or Other Pacific Islander000000000
Black or African American1212143216
White4444423429
More than one race000000000
Unknown or Not Reported101010003
Region of Enrollment
Region of Enrollment(participants)Adolescents, 5 mgAdolescents, 10 mgAdolescents, 15 mgAdolescents, 20 mgChildren, 5 mgChildren, 10 mgChildren, 15 mgChildren, 20 mgTotal
United States6663466643
Germany000320005
08

Study locations

7 sites
  • US003
    Washington, District of Columbia 20010, United States
  • US004
    Wichita, Kansas 67214, United States
  • US002
    Cincinnatti, Ohio 45219, United States
  • US001
    Cleveland, Ohio 44106, United States
  • DE002
    Berlin, 10249, Germany
  • DE001
    Mainz, 55122, Germany
  • DE003
    Ulm, 89075, Germany
09

References and documents

Publications

  • Findling RL, Robb AS, DelBello MP, Huss M, McNamara NK, Sarkis EH, Scheffer RE, Poulsen LH, Chen G, Lemming OM, Auby P. A 6-Month Open-Label Extension Study of Vortioxetine in Pediatric Patients with Depressive or Anxiety Disorders. J Child Adolesc Psychopharmacol. 2018 Feb;28(1):47-54. doi: 10.1089/cap.2017.0047. Epub 2017 Oct 16. PubMed 29035574 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Dec 2014 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2016, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2011
First posted
Dec 13, 2011
Start
Apr 2012
Primary completionActual
Dec 2014
CompletionActual
Jun 2015
Results first posted
Jan 15, 2016
Last update
Mar 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01491035
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Dec 13, 2011
Start date
Apr 2012
Primary completion
Dec 2014
Completion
Jun 2015
Results posted
Jan 15, 2016
Last update
Mar 16, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion